AF
APLS

Amalgamated Financial’s Apellis Pharmaceuticals APLS Stock Holding History

Amalgamated Financial’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$633K Buy
+12,464
New +$550K 0.01% 1419

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's APLS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2022: 12,464 shares worth $633K. The stake represents 0.01% of the portfolio and ranks #1419 among its holdings.

212 funds tracked by Wall St. Rank hold APLS as of Q1 2022.

  • Amalgamated Financial held 12,464 shares of Apellis Pharmaceuticals worth $633K as of Q1 2022.
  • Apellis Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Apellis Pharmaceuticals made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1419 holding.
  • 212 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.